Introduction {#s1}
============

Epilepsy is a very common neurological disorder in need of better therapies. Approximately one third of epilepsy patients are resistant to pharmacological treatments, and most of the current therapies can produce very severe side effects. One very effective alternative treatment is a very low carbohydrate, high fat diet---the ketogenic diet ([@bib47]; [@bib88]; [@bib115]). On a ketogenic diet, fatty acids are converted to the ketone bodies β-hydroxybutyrate and acetoacetate, which circulate at millimolar concentrations in the blood. These ketone bodies provide an alternative fuel to tissues, including the brain ([@bib27]; [@bib79]; [@bib90]; [@bib130]). The observation that increased ketone body metabolism produces seizure protection suggests that fuel utilization and neuronal excitability are linked, however, the mechanisms underlying this link are poorly understood ([@bib16]). Some of the mechanisms proposed to underlie this metabolic seizure protection include changes in gene expression associated with decreases in glycolysis ([@bib40]; [@bib111]), glutamate release reduction ([@bib60]), adenosine signaling through A1 purinergic receptors ([@bib77]), regulation of excitability by the activity of lactate dehydrogenase ([@bib101]), more efficient production of GABA from glutamate ([@bib127], [@bib126]), stimulation of mitochondrial biogenesis ([@bib15]), general 'positive' shifts in energy balance ([@bib15]; [@bib27]; [@bib91]), increase of GABAergic tonic inhibition through neurosteroids ([@bib38]), and a decrease in neuronal excitability mediated by metabolically sensitive ATP-sensitive potassium channels ([@bib41]).

To study how brain metabolism can modify neuronal excitability we have used a non-dietary approach to alter brain fuel utilization. The protein BAD ([B]{.ul}CL-2 [a]{.ul}gonist of cell [d]{.ul}eath) regulates both apoptosis and glucose metabolism ([@bib43]). When BAD's metabolic function is disrupted by genetic alteration in mice, neurons and astrocytes display decreased glucose and increased ketone body metabolism. These effects on brain metabolism produced by BAD alteration are reminiscent of those observed with a ketogenic diet. In fact, BAD-altered mice are also strongly resistant to behavioral and electrographic seizures. At the cellular level, BAD modifications that decrease glucose metabolism produce a marked increase in the activity of ATP-sensitive potassium (K~ATP~) channels located in dentate granule neurons (DGNs). Thus, K~ATP~ channels in the dentate gyrus, a region that is thought to limit input into the hippocampus acting as a seizure 'gate,' are well poised to mediate the effects of BAD on DGN excitability. Indeed, when K~ATP~ channels are genetically ablated, seizure resistance produced by BAD modification is abolished ([@bib41]).

In this study, we asked if BAD can effectively alter neuronal and network excitability by opening K~ATP~ channels. In BAD knockout mice, we restored BAD expression in a fraction of the DGNs, and tested individual cells to learn whether BAD could regulate K~ATP~ channel activity in a cell-autonomous manner. We also tested the consequences of altered K~ATP~ channel activity for excitability of individual DGNs, which we measured using perforated patch recordings in the presence or absence of the K~ATP~ channel inhibitor glibenclamide. Finally, to study the anticonvulsant effect of BAD in the entorhinal-hippocampal (EC-HC) circuit, we provoked epileptiform activity by partially blocking GABA~A~-mediated inhibition with picrotoxin, and monitored the activity using imaging of the calcium sensor GCaMP6f. BAD ablation reduced the epileptiform activity of the EC-HC circuit, and this seizure-protective effect depended on the presence of functional K~ATP~ channels. Furthermore, this in vitro seizure protection was reproduced by BAD deletion solely in DGNs, reinforcing the notion of the dentate gyrus as a seizure gate.

Results {#s2}
=======

The effect of BAD on K~ATP~ channels is cell-autonomous {#s2-1}
-------------------------------------------------------

To test whether the effects of BAD on K~ATP~ channels are cell-autonomous, we reconstituted BAD expression in the hippocampus of *Bad^−/−^* mice through intracranial injection of an adeno-associated virus (AAV). In addition to *Bad*, the AAV also contained the sequence for the red fluorescent protein mCherry to label transduced cells. To assess the effect of BAD on neuronal K~ATP~ channels, we performed whole-cell patch-clamp experiments using an intracellular solution with a high ATP concentration (4 mM) ([Figure 1A](#fig1){ref-type="fig"}). We have previously shown that *Bad* deletion produces an increase in K~ATP~ channel activity ([@bib41]). This increase is manifested at the whole-cell level as an initial K~ATP~ conductance that gradually decreases over the first few minutes of recording after break-in, as the intracellular solution is dialyzed with a sufficiently high ATP concentration to inhibit the initially open K~ATP~ channels; we have called this phenomenon 'washdown' ([@bib41]). In wild-type DGNs, because K~ATP~ channels display a very low basal open probability (NP~o~ = 0.05%), intracellular solution replacement with high ATP has no effect, so whole-cell conductance in this case remains unchanged after break-in, that is, washdown is absent in wild-type DGNs.

![Effect of BAD on K~ATP~ channels is cell-autonomous.\
(**A**) Left: schematic representation of intracranial injection of AAV.Bad.2A.mCherry in the hippocampus of *Bad^−/−^* mice to reconstitute BAD expression in mCherry labeled cells. Right: epifluorescence picture of a BAD-reconstituted *Bad^−/−^* DGN being recorded with a patch electrode (p.e.) in the whole-cell mode. Regions observed in picture: hilus, dentate granule cell layer (DGNs) and molecular layer (m.l.). (**B**) 'Washdown' of an initially high K~ATP~ conductance, with high ATP (4 mM) in the patch electrode, seen in *Bad^−/−^* but not BAD-reconstituted *Bad^−/−^* cells. The time course of slope conductance measured during whole-cell recording was normalized to the value 3 min after break-in. Data are presented as mean ± SEM.](elife-32721-fig1){#fig1}

If BAD modification leads to an increase in K~ATP~ channel activity in DGNs in a cell-autonomous manner, washdown is expected in unlabeled *Bad^−/−^* cells but not in mCherry-labeled BAD-reconstituted *Bad^−/−^* cells. Indeed, *Bad^−/−^* DGN whole-cell conductance displayed a gradual decrease during the first minute after break-in and then remained unchanged ([Figure 1B](#fig1){ref-type="fig"}). In contrast, BAD-reconstituted *Bad^−/−^* DGNs did not display washdown ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We also performed control experiments with low ATP (0.3 mM) in the pipette solution to measure the maximal activatable K~ATP~ conductance. In this case, if cells are not adversely affected by the overexpression of BAD and/or mCherry, *Bad^−/−^* and BAD reconstituted *Bad^−/−^* DGNs should display normal K~ATP~ channel current 'run-up' as channels become disinhibited when ATP is dialyzed out of the cell. Indeed, both transduced and untransduced cells displayed increases of K~ATP~ conductance of similar magnitudes ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) showing that the change in K~ATP~ currents is not due to a change in channel number, but rather to a change in channel open probability. This experiment also confirms that *Bad^−/−^* and BAD reconstituted *Bad^−/−^* DGNs are sufficiently healthy to maintain ATP levels that keep most (if not all) of their K~ATP~ channels closed. These results indicate that BAD can modulate K~ATP~ channel activity in a cell-autonomous manner.

K~ATP~ channels acutely modulate dentate granule neuron excitability {#s2-2}
--------------------------------------------------------------------

We then asked whether modulation of K~ATP~ channel activity could produce changes in neuronal electrical excitability. To examine DGN excitability, we performed current-clamp experiments in acute hippocampal slices. To preserve intracellular ATP dynamics, we used the perforated-patch technique to prevent dialysis of the cell's intracellular medium. In response to increasing current injections, *Bad^−/−^* DGNs generated fewer action potentials compared to wild-type DGNs ([Figure 2A,B](#fig2){ref-type="fig"}). Given that, in intact cells with physiological intracellular ATP levels, K~ATP~ channels are more active in *Bad^−/−^* cells and almost completely inactive in wild-type cells, application of glibenclamide, a K~ATP~ inhibitor, should increase excitability of *Bad^−/−^* neurons but produce minimal effects in wild-type. As predicted, after application of 200 nM glibenclamide, *Bad^−/−^* DGNs fired more action potentials, comparable to the response of wild-type DGNs (in the absence of glibenclamide). In contrast, the number of action potentials produced by wild-type DGNs was indistinguishable in the presence or absence glibenclamide ([Figure 2A,B](#fig2){ref-type="fig"}). These results provide evidence that K~ATP~ channels can regulate DGN excitability in an acute manner. Thus, deletion of BAD could produce seizure-protective effects by decreasing neuron excitability, via modulation of K~ATP~ channels.

![Dentate granule neurons lacking BAD are less excitable.\
(**A**) *Bad^−/−^* DGNs fire fewer action potentials that wild-type (WT), and 200 nM glibenclamide reverses *Bad* knockout effect on DGN excitability. Representative perforated-patch voltage recordings in response to a 1 s, 150 pA current pulse for WT and *Bad^−/−^* DGNs, in the presence or absence of 200 nM glibenclamide, as indicated. Dotted lines indicate 0 mV. (**B**) Glibenclamide application increases firing of *Bad^−/−^* DGNs but not that of WT. Number of action potentials (mean ± SEM) plotted against magnitude of current injection pulse. \*p\<0.05; 1-way ANOVA.](elife-32721-fig2){#fig2}

BAD and K~ATP~ channels regulate entorhinal-hippocampal epileptiform activity {#s2-3}
-----------------------------------------------------------------------------

Does the decrease in neuronal excitability mediated by K~ATP~ channels translate to a decrease in excitability at the network level? We have previously shown that global *Bad* deletion produces seizure resistance in vivo ([@bib41]). To gain a more profound understanding of the seizure-protective mechanisms elicited by BAD knockout, we performed experiments in acute brain slices containing both the entorhinal cortex (EC) and the hippocampus. To examine the excitability of the EC-HC network, we monitored intracellular calcium dynamics in acute EC-HC slices with the fluorescent sensor GCaMP6f delivered by AAV. We elicited seizure-like events (SLEs) by application of 2.5 µM picrotoxin, a GABA~A~ receptor antagonist. Seizure-like activity is notoriously challenging to elicit in acute slices using submersion chambers, due to lack of sufficient oxygenation ([@bib57]; [@bib58]; [@bib55]). To overcome this limitation, we used a double perfusion chamber in which EC-HC slices are exposed to the extracellular solution on both sides. The flow of the oxygen-saturated extracellular solution is sufficiently high (5 ml/min) to permit an adequate oxygenation of the slice and reliably elicit seizure-like events in the presence of picrotoxin ([Figure 3](#fig3){ref-type="fig"} and [Video 1](#video1){ref-type="video"}).

![Deletion of BAD reduces picrotoxin-elicited epileptiform activity.\
(**A**) Top: Schematic representation of the analyzed regions of interest in EC-HC acute slices; dentate gyrus/hilus (DGH), CA3, CA1, medial entorhinal cortex (MEC) and lateral entorhinal cortex (LEC). Bottom: representative epifluorescence images of an EC-HC slice expressing GCaMP6f in ACSF (Control; left) or in the presence of 2.5 µM picrotoxin as a SLE is occurring (right). (**B**) Picrotoxin application triggers SLEs. Representative ΔF/F traces (normalized from 0 to 1) in wild-type (WT; top) or *Bad^−/−^* (bottom) slices for the indicated regions of interest. The arrows indicate extracellular application of 2.5 µM picrotoxin in the extracellular bath. (**C**) Genetic deletion of BAD reduced the time EC-HC slices spent in SLEs, and this effect was mediated by K~ATP~ channels. Fraction of time spent in SLEs (mean ± SEM) plotted versus time (left column) or percent time in SLEs calculated from the 40--80 min range when seizure-like activity plateaus (right column) for each region of interest analyzed, and genotypes and conditions specified. \*p\<0.05; \*\*p\<0.005; \*\*\*p\<0.0005; 1-way ANOVA.](elife-32721-fig3){#fig3}

###### Seizure-like events in the presence of 2.5 μM picrotoxin.

Fluorescence intensity as imaged in [Figure 3](#fig3){ref-type="fig"} showing epileptiform activity in an acute EC-HP slice in the presence of 2.5 μM picrotoxin. Video was created using ImageJ 1.51 s (Fiji).

10.7554/eLife.32721.008

We observed GCaMP6f expression over the whole EC-HC area ([Figure 3A](#fig3){ref-type="fig"}) and detected clear seizure-like events throughout the slice, which for analysis we divided into three hippocampal areas: dentate gyrus and hilus (DGH), CA3, and CA1 and 2 EC areas: medial entorhinal cortex (MEC) and lateral entorhinal cortex (LEC). We applied picrotoxin after monitoring 10 min of baseline activity. Following picrotoxin application, SLEs started to appear in the five EC-HC regions mentioned ([Figure 3B](#fig3){ref-type="fig"}, top and [Video 1](#video1){ref-type="video"}). This behavior is consistent with previous reports that have used electrophysiological techniques to monitor epileptiform activity in the EC-HC network using various in vitro paradigms. We have also corroborated that the SLEs we observe by GCaMP6f fluorescence intensity changes (ΔF/F) faithfully mirror local electrical field potentials typically observed in this preparation ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). To analyze ΔF/F traces, we first filtered the signal to account for baseline drift, then set a threshold above which seizure-like activity was detected, and plotted the fraction of time spent in SLEs during the time of the experiment.

*Bad^−/−^* slices spent significantly less time in SLEs compared to wild-type slices ([Figure 3C](#fig3){ref-type="fig"}). Furthermore, the protection from picrotoxin-elicited epileptiform activity produced by BAD was abolished by genetic deletion of the pore-forming subunit of K~ATP~ channels, Kir6.2 (*﻿Kcnj11*﻿), or by continuous application of the K~ATP~ channel inhibitor, glibenclamide ([Figure 3C](#fig3){ref-type="fig"}). These observations show that *Bad* deletion prevents seizure-like activity and that K~ATP~ channels acutely mediate BAD's seizure-protective effects.

It has been shown that long-term synaptic depression mediated by postsynaptic NMDA receptors is abolished in hippocampal slices from *Bad^−/−^* mice ([@bib59]). However, given that we observe no significant differences between the genotypes when K~ATP~ channels are pharmacologically inhibited or genetically deleted, our results confirm that any genotype-specific differences in glutamatergic transmission are not affecting the seizure phenotype we observe (see also [@bib41]).

Given that BAD's antiseizure effect in vivo was previously demonstrated in adult mice, we wondered if BAD-dependent protection against SLEs also occurred in adult EC-HC slices. For this, we expressed GCaMP6f in the EC-HC region through AAV delivery at age P1-2 and monitored intracellular calcium in wild-type or *Bad^−/−^* acute slices obtained at age P60-90 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). In this case, a 20-fold higher picrotoxin concentration (50 µM) was needed to elicit a roughly similar epileptiform activity in adult EC-HC slices ([Figure 4](#fig4){ref-type="fig"}). This may be due to diverse factors, including the maturation of the inhibitory circuits that regulate EC-HC network excitability and maturation of DGNs themselves, which become intrinsically less excitable when fully mature in adult animals. Regardless of the picrotoxin concentration needed to elicit SLEs, deletion of *Bad* also protected against SLEs in adult EC-HC slices. There was a marked decrement in time spent in SLEs in the hippocampus, though this effect was not as strong in entorhinal areas ([Figure 4](#fig4){ref-type="fig"}). These results corroborate the anti-SLE effects of BAD in the adult EC-HC circuit.

![Deletion of BAD decreases picrotoxin-triggered seizure-like activity in adult EC-HC slices.\
Genetic deletion of BAD reduced the time hippocampal regions spent in SLEs in adult slices. Left column: fraction of time spent in SLEs (mean ± SEM) plotted versus time. The arrows indicate extracellular application of 50 µM picrotoxin in the extracellular bath. Right column: percent time in SLEs calculated from the 40--80 min range when seizure-like activity plateaus for each region of interest analyzed and genotypes specified. \*p\<0.05; \*\*p\<0.005; two-tailed Student's *t*-test.](elife-32721-fig4){#fig4}

Targeted BAD knockout in the dentate gyrus reduces seizure-like activity {#s2-4}
------------------------------------------------------------------------

So far, we have observed that BAD knockout in the entire mouse leads to reduced excitability in brain slices; we proceeded to ask whether BAD knockout in a restricted subset of cells could reproduce this effect. The dentate gyrus has been proposed to act as seizure gate, preventing epileptiform activity initiated in the EC from passing onto other hippocampal areas such as CA3 or CA1. Therefore, it is possible that decreasing DGN excitability alone would be sufficient to 'strengthen' the dentate gyrus' gate function, and thus decrease excitability in the EC-HC circuit responsible for many types of seizures, such as in temporal lobe epilepsy.

To test if BAD deletion in DGNs alone is sufficient to produce a decrease in picrotoxin-induced SLEs, we produced conditional knockout BAD mice (*Bad^flox/flox^*) and crossed them with transgenic mice (*Dock10-Cre*) that express Cre recombinase specifically in DGNs ([@bib63]). These mice (*Bad^flox/flox^; Dock10-Cre*) have targeted knockout of *Bad* expression in the dentate gyrus but not in the rest of the hippocampus or EC, as confirmed by immunostaining ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Compared to slices from both parental lines, *Bad^flox/flox^; Dock10-Cre* slices (from juvenile, P13-19, mice) spent significantly less time in SLEs ([Figure 6](#fig6){ref-type="fig"}). Remarkably, the reduction in seizure-like activity of these slices that lack BAD solely in DGNs was comparable to that of *Bad^−/−^* slices (compare orange *Bad^flox/flox^; Dock10-Cre* and green *Bad^−/−^* data in [Figure 6](#fig6){ref-type="fig"}). These results demonstrate that DGN-specific BAD knockout is sufficient to produce alleviation of seizure-like activity, supporting the idea that BAD's direct action in neurons can produce seizure protection. Furthermore, the results provide additional evidence to support the idea that the dentate gyrus acts as a gate for seizure activity.

![Targeted knockout of *Bad* expression in the dentate gyrus but not in the rest of the hippocampus.\
(**A**) Schematic illustration of the targeting construct and strategy to generate the conditional *Bad^flox^* allele. *Abbreviations*: En2 SA: En2 splice acceptor; IRES: Internal ribosomal entry site; pA: polyadenylation sequence; Frt: Flipase (Flpe) recombinase target; loxP: Cre recombinase target; hBactP: human beta actin promoter; NEO: neomycin resistance gene. (**B, C, D**) Immunostaining for BAD in brain coronal sections from mice of the specified genotypes. Notice lack of BAD expression only in DGNs from *Bad^flox/flox^; Dock10-Cre* brain. In the right column dashed line area demarcates the DGN cell body layer. Also notice the lower fluorescence intensity in the entire molecular layer of the dentate gyrus (containing the dendrites of the DGNs) in *Bad^flox/flox^; Dock10-Cre* compared to the parental genotypes.](elife-32721-fig5){#fig5}

![DGN-specific BAD ablation is sufficient to reduce seizure-like activity.\
Genetic deletion of *Bad* in DGNs alone (*Bad^flox/flox^; Dock10-Cre*, orange) reduced the time hippocampal regions spent in SLEs in adult slices. Left column: fraction of time spent in SLEs (mean ± SEM) for *Bad^flox/flox^; Dock10-Cre* (orange), *Dock10-Cre* (dark magenta) or *Bad^flox/flox^* (teal) plotted versus time. For comparison, WT (black) and *Bad^−/−^* (green) data are reproduced from [Figure 3](#fig3){ref-type="fig"} as dashed lines without error bars. Right column: percent time in SLEs calculated from the 40--80 min range when seizure-like activity plateaus for each region of interest analyzed. \*p\<0.05; \*\*p\<0.005; \*\*\*p\<0.0005; 1-way ANOVA.](elife-32721-fig6){#fig6}

Discussion {#s3}
==========

Seizure protection can be elicited by manipulation of brain metabolism {#s3-1}
----------------------------------------------------------------------

Alterations in metabolism have long been proposed as avenues to treat epileptic seizures. One example is the ketogenic diet, which has been used for almost a century as an effective treatment for epilepsy ([@bib47]; [@bib88]; [@bib115]). The switch in brain fuel metabolism from using carbohydrates to ketone bodies appears to be a major contributor to seizure protection. Compared to control animals, rats on a low-carbohydrate, high-fat diet exhibit lower glucose and increased ketone body concentrations in blood. These ketotic rats show altered brain levels of metabolites, such as the whole brain ATP/ADP ratio, suggesting an 'improved' energy state ([@bib27]). Further, rats on the ketogenic diet upregulate transcripts encoding mitochondrial energy metabolism enzymes ([@bib15]). Human patients undergoing treatment with a ketogenic diet also show changes in brain energy metabolism in agreement with rodent studies ([@bib91]). The role of this metabolic switch in producing seizure protection is supported by the fact that although the anticonvulsive effect of the ketogenic diet develops gradually over days, it can be reversed in rodents and humans very rapidly upon carbohydrate consumption ([@bib6]; [@bib56]; [@bib94]; [@bib117]). A different manipulation of brain metabolism by pharmacological inhibition of glycolysis also leads to seizure protection. The glycolytic inhibitor 2-deoxy-D-glucose (2DG) suppresses rodent seizures in vivo and in vitro through changes in gene expression related to epilepsy ([@bib40]; [@bib111]), thus reinforcing the idea that metabolic changes can produce seizure-protective effects.

Changes in metabolism mediated by BAD produce seizure resistance {#s3-2}
----------------------------------------------------------------

We have used a *Bad^−/−^* mouse model with effects on brain metabolism that are very reminiscent of those of the ketogenic diet; this non-dietary manipulation permits the investigation of the mechanisms involved in metabolic seizure resistance. *Bad^−/−^* mice are resistant to acute seizures induced by either intraperitoneal injection of kainic acid, an agonist of a subclass of ionotropic glutamate receptors, or subcutaneous injection of pentylenetetrazole, an antagonist of GABA~A~ receptors ([@bib41]). Because these two pharmacologic models of *status epilepticus* act through different mechanisms, producing seizures with different characteristics, indicating that the seizure resistance produced by *Bad* deletion can be effective in different types of epilepsy. We have also shown that *Bad* deletion can reduce seizures and increase longevity in a genetic mouse model of epilepsy and sudden unexplained death in epilepsy ([@bib37]).

BAD is a proapoptotic BCL-2 family member, but in addition to its well-known proapoptotic action, BAD also regulates glucose metabolism in various cell types ([@bib43]). The switch between the apoptotic and metabolic roles of BAD occurs through phosphorylation of its serine 155 (equivalent to serine 118 in human BAD) ([@bib26]). Serine 155 phosphorylation enhances glucose metabolism while inhibiting BAD's apoptotic function. Mutation of this residue to a non-phosphorylatable alanine (*Bad*^S155A^) phenocopies the glucose-to-ketone-body fuel switch in BAD knockout neurons and astrocytes, and also produces in vivo seizure protection ([@bib41]). Because both *Bad^−/−^* and *Bad*^S155A^ have the same effects on K~ATP~ channel activity and seizure protection, but have opposite effects on apoptosis, the effects of BAD knockout on seizure-like activity are very likely due to BAD's effect on metabolism and not on apoptosis.

Studies in mouse models with deletions in other BCL-2 family members provide further evidence that BAD-mediated seizure protection is metabolic rather than apoptotic. Knockout of BIM or PUMA leads to neuroprotection related to seizures ([@bib35], [@bib34]; [@bib87]). However, in contrast to our previous observations of seizure protection by BAD deletion ([@bib41]), ablation of BIM or PUMA is not seizure protective immediately after kainic acid injection ([@bib34]; [@bib87]). Instead, these other BCL-2 family members, promote hippocampal neuron death in a model of chronic seizures (intra-amygdala microinjection of kainic acid), thus, *Bim^−/−^* or *Puma^−/−^* animals exhibit long-term seizure protection due to decreased cell death, as opposed to *Bad^−/−^* mice that are resistant to acute seizures due to a switch in fuel preference.

Effects of BAD deletion are acutely mediated by K~ATP~ channels {#s3-3}
---------------------------------------------------------------

The metabolic shift produced by BAD knockout leads to an increase in K~ATP~ channel activity. In cell-attached recordings from DGNs, where the intracellular medium---and thus ATP---is undisturbed, the open probability of K~ATP~ channels is markedly increased in *Bad^−/−^* cells compared to wild-type cells, where these channels are mostly closed ([@bib41]). Furthermore, the extra whole-cell conductance due to this increased K~ATP~ channel activity in *Bad^−/−^* DGNs can be seen to disappear as the intracellular medium is dialyzed with an elevated ATP concentration ([Figure 1](#fig1){ref-type="fig"}), an effect absent in wild-type DGNs ([@bib41]).

The altered K~ATP~ conductance is due to the change in open probability and not to a change in the number of functional K~ATP~ channels. In whole-cell experiments with low ATP in the intracellular medium, the maximal conductance measured after disinhibition of the channels is very similar in wild-type and *Bad^−/−^* DGNs ([@bib41]) and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

Furthermore, K~ATP~ channels are required for the anti-seizure effect of *Bad* deletion. There is a reversal of seizure protection in *Bad^−/−^* mice upon further deletion of *Kcnj11* (Kir6.2), the pore-forming subunit of neuronal K~ATP~ channels ([@bib41]). More specifically, the susceptibility of *Bad^−/−^; Kcnj11^−/−^* double knockout mice to kainic acid induced seizures is comparable to that of wild-type mice, providing compelling evidence that K~ATP~ channels are required for BAD-mediated seizure resistance.

Here we found that the increased K~ATP~ conductance leads to decreased DGN excitability ([Figure 2](#fig2){ref-type="fig"}). Previously, K~ATP~ channels have been seen to affect neuronal excitability ([@bib3]; [@bib46]; [@bib96]). K~ATP~ channels link metabolism to excitability because they are inhibited by intracellular ATP, and activated by intracellular ADP ([@bib1]; [@bib89]; [@bib97]). They are also widely expressed in the brain ([@bib33]; [@bib69]) and are present at a particularly high density in DGNs ([@bib61]; [@bib86]; [@bib128]), where their single-channel activity can be readily recorded ([@bib41]; [@bib93]; [@bib114]).

The regulation of neuronal excitability by K~ATP~ channels has been extensively studied in the context of protection from hypoxia or ischemia: these channels prevent prolonged depolarizations that produce neuronal damage ([@bib113]; [@bib112]; [@bib124]). Additionally, they are crucial in the response of hypothalamic neurons to circulating glucose levels ([@bib7]; [@bib67]; [@bib82]; [@bib99]; [@bib109]). Our results show that K~ATP~ channels can acutely modulate DGN excitability at the cellular level ([Figure 2](#fig2){ref-type="fig"}) as well as network excitability in slices that are disinhibited by picrotoxin to exhibit seizure-like events ([Figure 3](#fig3){ref-type="fig"}). This acute pharmacological reversal of DGN excitability supports the role of neuronal K~ATP~ channels as key molecules mediating seizure protection ([@bib41]; [@bib124]).

Targeted *Bad* deletion in the DGNs is sufficient to produce seizure protection {#s3-4}
-------------------------------------------------------------------------------

We also show that eliminating *Bad* specifically in the brain can lead to changes in K~ATP~ channel activity and network excitability. When BAD was restored in single *Bad^−/−^* DGNs via AAV, K~ATP~ channel activity reverted to that of wild-type DGNs ([Figure 1](#fig1){ref-type="fig"}), signifying that BAD's effect on neurons can be reversed in a cell-autonomous manner and does not seem to depend on other types of brain cells, such as astrocytes. At the network level, we show that either global knockout or DGN-targeted knockout of BAD produced a decrease in picrotoxin-induced seizure-like activity ([Figures 3](#fig3){ref-type="fig"} and [6](#fig6){ref-type="fig"}), and this effect was mediated by K~ATP~ channels. This suggests that BAD's action in specific neuronal populations may alleviate seizures. However, it is yet to be tested whether *Bad* deletion solely in DGNs produces seizure protection in vivo. Future in vivo studies involving targeted *Bad* deletion in different neuron populations are needed to pinpoint whether additional brain regions are necessary for the BAD-mediated antiseizure effect.

BAD modulates a seizure gate in the dentate gyrus {#s3-5}
-------------------------------------------------

The K~ATP~-mediated decrease in DGN excitability elicited inhibition of network excitability, consistent with the seizure protection observed in BAD-altered mice. The dentate gyrus controls the input from the entorhinal cortex into the rest of the hippocampus; ictal activity can be initiated in the EC and propagate through the dentate gyrus to CA3 and/or CA1. Furthermore, because of the recurrent connectivity of the EC-HP circuit due to the afferents from CA1 to the EC that pass through the subiculum, excitation can then re-enter the EC ([@bib4]; [@bib10]; [@bib9]; [@bib11]; [@bib110]; [@bib118]). In this way, the effect of the dentate gate in principle may be observed by decreased excitation not only throughout the hippocampus but also extending to the EC, as we observe in this study. Thus, limiting DGN excitability could lead to seizure protection by 'strengthening' the dentate gate. It has also been observed that ictal activity could either directly propagate from the EC to CA1 ([@bib5]) or originate in the dentate and subsequently spread to the EC ([@bib73]; [@bib80]). Our observations of a BAD-dependent decrease in time spent in SLEs are consistent with this picture ([Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Further, we found that *Bad* deletion specific to the dentate was sufficient to elicit protection from picrotoxin-triggered SLEs. Remarkably, EC-HC slices from mice lacking BAD exclusively in DGNs displayed a similar reduction in seizure-like activity to that of slices from mice in which BAD had been globally knocked-out ([Figure 6](#fig6){ref-type="fig"}).

Our immunostaining results show robust BAD knockout in DGNs (including stratum lucidum, which contains the mossy fiber projections from DGNs) of *Bad^flox/flox^; Dock10-Cre* mice compared to the parental controls ([Figure 5](#fig5){ref-type="fig"}). This targeted *Bad* knockout had no discernable effect on BAD expression elsewhere in the brain slices we examined. We cannot rule out that very sparse expression of *Dock10-Cre* in the EC (Allen Institute Mouse Brain Atlas; expression of *Dock10*) could affect some cells, however, the absence of *Bad* throughout the DGN layer of *Bad^flox/flox^; Dock10-Cre* mice, together with the substantial effect on the seizure-like activity, seems most consistent with a primary effect of the dentate acting as a seizure gate, as suggested previously from both in vitro and in vivo experiments ([@bib28]; [@bib49]; [@bib54]; [@bib65]; [@bib64]; [@bib71]). Interestingly, seizure-like activity is decreased in all areas (including EC) of the EC-HC slices upon BAD knockout specifically in DGNs; as previously mentioned this could reflect the recurrent nature of the EC-HC circuit where the dentate gate could decrease reentrant excitation into the EC. Taken together, these observations illuminate a mechanism by which neuronal metabolism can regulate neuronal excitability to produce seizure protection.

BAD-mediated seizure protection remains throughout brain development {#s3-6}
--------------------------------------------------------------------

Mechanisms of both seizure production and seizure protection appear to change throughout brain development ([@bib28]; [@bib51]). Consistent with this, we observed that a 20-fold higher picrotoxin concentration is required to elicit robust SLEs in adult slices compared to juvenile ([Figure 4](#fig4){ref-type="fig"}). In the juvenile mouse brain, most DGNs are immature and still integrating into the circuit; they are more excitable than mature cells and have yet to fully develop their inhibitory connections ([@bib36]; [@bib85]; [@bib95]; [@bib102]). Our results are also consistent with developmental changes in GABAergic signaling, including the shift from a depolarizing to a hyperpolarizing chloride current during brain maturation ([@bib12]; [@bib50]; [@bib70]; [@bib98]; [@bib125]).

We also observed that in adults, BAD-mediated seizure resistance is more limited to the hippocampal region and is not as prominent in the EC ([Figure 4](#fig4){ref-type="fig"}). This pattern is consistent with BAD-mediated reinforcement of a dentate gate that limits invasion of elevated EC activity into the hippocampus. The fact that in juvenile slices, DGN-specific deletion of BAD also affected EC activity may indicate that, at the lower levels of disinhibition (lower \[picrotoxin\]), recurrent excitation from the hippocampus to EC is more relevant than in adult slices.

BAD knockout leads to K~ATP~ channel activation by several possible mechanisms {#s3-7}
------------------------------------------------------------------------------

The detailed mechanism by which BAD knockout influences K~ATP~ channel activity is still unknown. One possibility is that although ATP in the whole brain of *Bad^−/−^* mice is not reduced ([@bib41]), the ATP concentration in a compartment local to the channels is reduced. Indeed, ATP consumption at the plasma membrane by the Na^+^/K^+^ pump can increase K~ATP~ channel opening ([@bib46]; [@bib114]). Further, glycolytic enzymes are associated with membrane proteins ([@bib30]; [@bib72]; [@bib78]; [@bib92]) and have been found to form a complex with K~ATP~ channels ([@bib29]; [@bib32]; [@bib52]). Glycolytic inhibition by application of 2DG produces a decrease in cellular and network excitability mediated by K~ATP~ channels and an increase of GABAergic tonic inhibition through neurosteroids ([@bib38]). Even though a direct interaction between BAD and the glycolytic enzyme hexokinase has not been studied, BAD interacts with glucokinase (hexokinase IV) in pancreatic β-cells and hepatocytes ([@bib26], [@bib25]; [@bib42]), and thus, could be affecting glycolytic ATP production through this interaction. Metabolites other than ATP, such as PIP~2~, also regulate K~ATP~ channels ([@bib68]; [@bib76]; [@bib104]; [@bib103]), and *Bad* deletion might modify the properties of K~ATP~ channels by altering PIP~2~ or through other mechanisms, such as phosphorylation ([@bib20]).

Conclusion {#s3-8}
----------

We have shown that K~ATP~ channels can acutely regulate cellular and network excitability, but whether BAD manipulation itself can affect excitability in an acute manner remains an open question. Inhibitory molecules of BAD's glycolytic role would be valuable to learn the time course by which BAD manipulation exerts its effect on K~ATP~ channels, and thus, seizure protection. Because K~ATP~ channels regulate a wide variety of processes in the brain, targeting the (still unknown) mechanisms that link the BAD-induced change in metabolism to excitability might prove a better pharmacological strategy than targeting neuronal K~ATP~ channels. Mimicking the effect of BAD knockout on fuel preference using small molecules could be a valuable avenue for development of new epilepsy therapies.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\      Designation                       Source or reference               Identifiers                                                    Additional information
  or resource                                                                                                                                                     
  ---------------------------- --------------------------------- --------------------------------- -------------------------------------------------------------- ------------------------
  Gene (*Mus musculus*)        *Bad*                             this paper                        HEPD0750_4\_D04                                                for generation of\
                                                                                                                                                                  *Bad^flox/flox^* mice

  Strain, strain background\   male or female C57BL/6 mice       Charles River Laboratories                                                                       
  (*Mus musculus*)                                                                                                                                                

  Genetic reagent\             male or female homozygous\        doi:10.1038/nm1717                                                                               
  (*Mus musculus*)             *Bad^−/−^* mice                                                                                                                    

  Genetic reagent\             male or female homozygous\        doi:10.1016/j.neuron.\                                                                           
  (*Mus musculus*)             *Bad^−/−^*; *Kcnj11^−/−^* mice    2012.03.032                                                                                      

  Genetic reagent\             female heterozygous\              doi:10.1038/nn.3614                                                                              
  (*Mus musculus*)             *Dock10-Cre^+/− ^*mice                                                                                                             

  Genetic reagent\             male or female homozygous\        this paper                                                                                       
  (*Mus musculus*)             *Bad^flox/flox^* mice                                                                                                              

  Genetic reagent\             male or female\                   this paper                                                                                       
  (*Mus musculus*)             heterozygous *Bad^flox/flox^*;\                                                                                                    
                               *Dock10-Cre^+/− ^*mice                                                                                                             

  Strain, strain background\   AAV2/8.CAG.BAD.2A.mCherry         BAD-2A-mCherry plasmid\                                                                          
  (*Adeno-associated virus*)                                     packed into AAV8 at Viral Core\                                                                  
                                                                 Boston Children's Hospital                                                                       

  Strain, strain background\   AAV2/9.CAG.GCaMP6f                Penn Vector Core                  Cat. no. AV-9-PV3081                                           
  (*Adeno-associated virus*)                                                                                                                                      

  Antibody                     anti-Bad (rabbit monoclonal)      Abcam                             ab32445;\                                                      (1:100)
                                                                                                   RRID:[AB_725614](https://scicrunch.org/resolver/AB_725614)     

  Antibody                     anti-Rabbit IgG\                  Sigma                             SAB4600107                                                     (1:1000)
                               (goat polyclonal), CF 594                                                                                                          

  Other                        VECTASHIELD mounting\             Vector Laboratories               H-1200;\                                                       
                               medium with DAPI                                                    RRID:[AB_2336790](https://scicrunch.org/resolver/AB_2336790)   

  Software                     MATLAB 2016b                      Mathworks                         RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)   

  Software                     Fiji/ImageJ 1.51 s                NIH                               RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)   

  Software                     Origin 9.1                        OriginLab                                                                                        

  Software                     Patchmaster v2x43                 HEKA                                                                                             

  Software                     TILLvisION 4.0.7.2                Thermo Fisher Scientific                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reagents {#s4-1}
--------

All reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Animals {#s4-2}
-------

Brain slice experiments were performed using brains of male and female wild-type mice (C57BL/6; Charles River Laboratories), *Bad^−/−^* mice ([@bib26]), *Bad^−/−^; Kcnj11^−/−^* mice ([@bib41]), *Dock10-Cre* mice ([@bib63]), *Bad^flox/flox^* mice (see below) or *Bad^flox/flox^; Dock10-Cre* mice. Animals were housed in a barrier facility in individually ventilated cages with ad libitum access to standard chow diet (PicoLab 5058). All experiments were performed in compliance with the NIH Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act. The Harvard Medical Area Standing Committee on Animals approved all procedures involving animals.

*Generation of* Bad^flox/flox^ *mice* {#s4-3}
-------------------------------------

The ES cell clone bearing the targeting vector of Bad gene (HEPD0750_4\_D04) was purchased from the European Conditional Mouse Mutagenesis Program, Helmholtz Center Munich, Germany (EUCOMM ID:92156). The targeted Bad allele contained an IRES:LacZ trapping cassette located 5' from a promoter-driven neomycin resistance cassette and inserted upstream of exon 3 flanked by loxP sites (knockout-first-allele design ([@bib108]); see also [Figure 5A](#fig5){ref-type="fig"}). This allele also contained frt sites to allow simultaneous removal of LacZ and Neo cassettes by Flipase (Flpe)-driven recombination to generate the conditional *Bad^flox^* allele.

Conditional *Bad^flox/flox^* mice were generated at the Center for Genome Modification at the University of Connecticut Health, Farmington, CT. Briefly, ES cells (MJ8) were microinjected into blastocysts (BALB/c) to generate chimeric mice that were then crossed to C57BL/6N to generate *BAD^flox-frt/+^* mice. *BAD^flox-frt/+^* mice were then crossed to Flpe mice to remove the lacZ reporter and Neo resistance cassettes. *Bad^flox/flox^* mice were then mated with *Dock10-Cre* mice ([@bib63]) to generate *Bad^flox/flox^;Dock10-Cre* mice in which *Bad* is selectively deleted in DGNs.

Viral vectors {#s4-4}
-------------

Custom‐made adeno-associated virus (AAV) vector AAV2/8.CAG.BAD.2A.mCherry was obtained from the Viral Core Facility in Boston Children's Hospital, Boston, MA. AAV2/9.CAG.GCaMP6f (Cat. no. AV-9-PV3081) was obtained from the or the Penn Vector Core, University of Pennsylvania, PA.

GCaMP6f expression in entorhinal-hippocampal area {#s4-5}
-------------------------------------------------

Mice at postnatal day 1 or 2 were anesthetized by cryoanesthesia. After confirmation of anesthesia, pups were injected intracranially in both hemispheres with 200 nl of either AAV2/8.CAG.BAD.2A.mCherry or AAV2/9.CAG.GCaMP6f. The injection coordinates with respect to lambda were: 0 μm in the anterior‐posterior direction, ±2.0 μm in the medial‐lateral axis and ‐2.0 μm in the dorsal‐ventral direction.

Hippocampal slice preparation for patch-clamp recordings {#s4-6}
--------------------------------------------------------

Juvenile (13 to 19 days old) mice were used for all patch clamp recordings. For BAD reconstitution experiments, mice were injected (at postnatal day 1 or 2) in both hemispheres with 200 nl of AAV2/8.CAG.BAD.2A.mCherry. Mice were anesthetized by isoflurane inhalation and decapitated into ice-cold slicing solution (in mM): 87 NaCl, 2.5 KCl, 1.25 NaH~2~PO~4~, 25 NaHCO~3~, 7 MgCl~2~, 0.5 CaCl~2~, 25 D-glucose, 75 sucrose and (osmolality \~340 mmol/kg). The hippocampus was isolated and mounted on a 5% agar cube which was then glued on the stage of a vibrating microtome (Campden Instuments 7000smz, Loughborough, England). Acute hippocampal slices 400 µm thick were cut in the transverse plane. Slices were then incubated at 37°C for 35 min in artificial cerebrospinal fluid (ACSF) containing (in mM): 120 NaCl, 2.5 KCl, 1 NaH~2~PO~4~, 26 NaHCO~3~, 1.3 MgCl~2~, 2.5 CaCl~2~, 10 D-glucose (\~300 mmol/Kg, pH 7.4). Additionally, all patch-clamp recording solutions contained 100 µM picrotoxin and 1 mM kynurenic acid to block fast synaptic transmission. These synaptic blockers were directly dissolved into ACSF immediately before experiments. After recovery, slices were stored at room temperature for 0 to 3 hr before use. All solutions were bubbled continuously with 95% O~2~ and 5% CO~2~.

Entorhinal-hippocampal slice preparation for epileptiform activity recordings {#s4-7}
-----------------------------------------------------------------------------

Juvenile (13 to 19 days old) or adult (60 to 90 days old) mice were injected (at postnatal day 1 or 2) in both hemispheres with 200 nl of AAV2/9.CAG.GCaMP6f. Mice were anesthetized by isoflurane inhalation and then decapitated. The brain was then placed in ice-cold slicing solution (in mM): 87 NaCl, 2.5 KCl, 1.25 NaH~2~PO~4~, 25 NaHCO~3~, 7 MgCl~2~, 0.5 CaCl~2~, 25 D-glucose, 75 sucrose and (osmolality \~340 mmol/kg) for juvenile mice or 93 N-Methyl-D-Glucamine, 2.5 KCl, 1.2 NaH~2~PO~4~, 30 NaHCO~3~, 10 MgCl~2~, 0.5 CaCl~2~, 25 D-glucose, 20 HEPES, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate (\~320 mmol/Kg; pH 7.4 adjusted with HCl) for adult mice ([@bib116]). Acute slices 450 µm thick were cut in the transverse plane using a vibrating microtome (Campden Instuments 7000smz, Loughborough, England). Slices were allowed to recover at 37°C for 35 min in artificial cerebrospinal fluid (ACSF) containing (in mM): 120 NaCl, 2.5 KCl, 1 NaH~2~PO~4~, 26 NaHCO~3~, 1 MgCl~2~, 2 CaCl~2~, 10 D-glucose (\~300 mmol/Kg, pH 7.4). After recovery, slices were stored at room temperature for 0 to 3 hr before use. All solutions were bubbled continuously with 95% O~2~ and 5% CO~2~. Picrotoxin was prepared daily before recordings from 50 or 500 mM stock solutions in DMSO and diluted to 2.5 or 50 µM, respectively, in recording solution. The concentration of DMSO as a vehicle control in ACSF was adjusted accordingly to 0.005% or 0.01%.

Patch-clamp recordings {#s4-8}
----------------------

Whole-cell and perforated-patch recordings from individual dentate granule neurons (DGNs) identified under infrared differential interference contrast (IR-DIC) visual guidance were made in voltage-clamp mode following establishment of high-resistance (multi-GΩ) seals. For BAD reconstitution experiments, mCherry was excited at 580 nm using a Xenon lamp and monochromator (Polychrome IV, Thermo Fisher Scientific). Images were collected with a CCD camera (IMAGO-QE, Thermo Fisher Scientific) and TILLvisION software (Thermo Fisher Scientific). Electrophysiological data were collected with a HEKA EPC 10 patch-clamp amplifier (HEKA, Holliston, MA). Currents were filtered at 1 kHz and sampled at 10 kHz. Patchmaster v2x43 software (HEKA, Holliston, MA) was used for amplifier control and data acquisition. Patch pipettes were pulled from borosilicate glass (VWR Scientific) using a Sutter Instruments P-97 puller. Pipette tips were fire polished to resistances of 2--3 MΩ when filled with recording solutions. During recording, ACSF was delivered to the recording bath using a peristaltic pump at a flow rate of 1 ml/min at room temperature.

For whole-cell recordings the pipette solution contained (in mM): 140 KMeS, 10 NaCl, 10 HEPES, 1 MgCl~2~, and 0.1 EGTA (osmolality \~295 mmol/kg; pH 7.4), supplemented with 0.3 mM NaGTP and either 0.3 or 4 mM MgATP. A voltage ramp protocol was used to measure input resistance and slope conductance: from the --70 mV holding potential followed two 100 ms steps first to --100 mV then to --120 mV before initiation of a 1 s ramp from --120 to --60 mV. The prepulses were used to calculate the cell's input resistance. Voltage ramps were applied every 10 s and fitted with a straight line from --120 to --90 mV to provide a running assessment of whole-cell slope conductance.

For perforated-patch recordings, the pipette tip was filled with whole-cell pipette solution and backfilled with the same solution with amphotericin B (200 µg/ml) and Alexa Fluor 488 (10 µM; Invitrogen) added. This solution was vortexed immediately before each neuron was patched. Giga-ohm seals were achieved before a amphotericin B arrived at the pipette tip, as assessed by monitoring Alexa Fluor 488 fluorescence. The access resistance was then continuously monitored and recordings started when the access resistance was \<100 MΩ. Experiments where access resistance changed \>20% during the experiment or seals that took longer than 15 min to perforate were discarded. The integrity of perforated-patch recordings was judged by monitoring Alexa Fluor 488 fluorescence, and recordings where dye entered the cell were discarded. To limit recordings to a population of neurons in a homogeneous stage of DGN maturation, perforated-patch experiments were performed in DGNs with membrane capacitance of 30--40 pF. Amphotericin B was stored at --20°C in 20 mg/ml stock solutions in DMSO for one week maximum. Glibenclamide (200 nM) was diluted in ACSF from a 0.5 mM stock solution in DMSO. DMSO as a vehicle control was added to ACSF at 0.02%. Glibenclamide was applied for 10 min before recording its presence. The current clamp protocol consisted on injecting sufficient current (\<30 pA) to maintain the membrane potential at --70 mV. A series of 1 s current pulses (10 s interval between pulses) were applied from 50 to 200 pA in 50 pA steps. Experiments were performed with experimenter blind to genotype.

Patch-clamp data analysis {#s4-9}
-------------------------

Data and statistical analysis were performed with Patchmaster v2x43 (HEKA, Holliston, MA) and Origin 9.1 (OriginLab, Northampton, MA, USA). The number of independent experiments (n) corresponds to the number of patched cells from different hippocampal slices. In all cases, each experimental condition was tested in slices from at least three different animals.

Epileptiform activity recordings {#s4-10}
--------------------------------

In our efforts to study seizure-like activity we devised a non-electrophysiological in vitro paradigm to monitor SLEs using the fluorescent calcium sensor GCaMP6f. Epileptiform activity in the EC-HC region has been extensively studied using electrophysiological methods in acute slices ([@bib8]). A plethora of methods to elicit epileptiform activity in EC-HC slices have been utilized, including inhibition of potassium channels with 4-aminopyridine ([@bib18]; [@bib19]; [@bib39]; [@bib81]; [@bib100]; [@bib119]; [@bib121]), dishinbiting glutamate receptors by lowering the extracellular magnesium concentration ([@bib17]; [@bib31]; [@bib62]; [@bib84]; [@bib120]; [@bib123]; [@bib129]), or inhibition of GABA~A~ receptors with picrotoxin ([@bib44]; [@bib45]; [@bib66]; [@bib83]). Compared to in vivo experiments, these seizure-like activity paradigms have several advantages, such as straightforward access to perfuse pharmacological agents and higher experimental throughput. We chose to study epileptiform activity by extracellular picrotoxin application due to the reliability of triggering SLEs slice to slice (SLEs were observed in all slices treated with picrotoxin), short latency of SLE induction and robustness of epileptiform bursts.

We sought to further increase throughput by avoiding placing electrodes in the preparation and increasing the spatial coverage of the area being monitored to the whole EC-HC region. The majority of the studies of epileptiform activity in brain slices have been performed using single-electrode extracellular recordings, planar multielectrode arrays ([@bib53]; [@bib106], [@bib105]), or tetrode wire recordings ([@bib75]). These methods, while having high temporal resolution, are limited to the number of electrodes that can be placed in the preparation, limiting the spatial coverage. To circumvent this constraint, in vitro epileptiform activity has also been investigated by optical methods including the monitoring of intrinsic optical signals ([@bib2]; [@bib14]; [@bib24]; [@bib122]) or fluorescence of voltage-sensitive dyes ([@bib13]; [@bib21]; [@bib22]; [@bib48]; [@bib107]). These optical methods allow for examination of seizure-like activity over a wide tissue area, however, their signal-to-noise ratio is poor and the dynamic range is very limited (a few percent), thus requiring significant signal averaging and decreasing even further temporal resolution. We expressed GCaMP6f, a fluorescent calcium sensor that has superior signal-to-noise ratio (typically a maximum of \~50% ΔF/F in our experiments) and with temporal dynamics adequate to discern picrotoxin-elicited SLEs ([@bib23]). To monitor epifluorescence in the entirety of the EC-HC network we used a low magnification (4X) objective which makes this technique straightforward.

It is technically challenging to sufficiently oxygenate brain slices to preserve network dynamics in submerged conditions ([@bib57]; [@bib58]; [@bib55]). In a typical submerged chamber, the slices are in contact with the bath solution only on one side, thus, to achieve sufficient oxygenation, very high perfusion rates (\>15 mL/min) are necessary to preserve network activity. To monitor epileptiform activity through GCaMP6f epifluorescence, we used a dual perfusion chamber, where acute slices are sitting in a grate in contact with oxygenated solution on both sides ([@bib57]; [@bib58]; [@bib74]). The dual perfusion chamber permits maintaining sufficiently high oxygenation for the generation of SLEs while also greatly facilitating imaging with an unsubmerged low-power objective to visualize the whole EC-HC area. In part this is due to perfusion rates (5 mL/min) that create a suitably undisturbed surface. This new in vitro setting greatly facilitates the study of epileptiform activity and can be easily modified to monitor other fluorescent sensors.

We recorded fluorescence intensity recordings in a dual-perfusion chamber where the slices are in contact with oxygenated ACSF on both sides continuously at a rate of 5 ml/min (2.5 ml/min/line) ([@bib58]). A slice anchor (Warner Instruments, Hamden, CT) was placed on each slice to prevent its movement during the experiment. Bath temperature was maintained at 34°C using one inline heater (Warner Instruments, Hamden, CT) per perfusion line. Solutions were kept in a water bath (VWR) at 37°C during the experiments to prevent out-gassing while being bubbled continuously with 95% O~2~ and 5% CO~2~. Slices were visualized with an Olympus BX51WI upright microscope using a 4X (NA 0.1 or 0.13) objective. GCaMP6f was excited at 485 nm using a Xenon lamp and monochromator (Polychrome IV, Thermo Fisher Scientific). Images were collected with a CCD camera (IMAGO-QE, Thermo Fisher Scientific) at a rate of 10 frames per second with TILLvisION software (Thermo Fisher Scientific).

Regions of interest were drawn with ImageJ (NIH) to analyze GCaMP6f fluorescence intensity changes (ΔF/F) in the entorhinal cortex or hippocampus. Subsequent analysis was performed using laboratory-made software in MATLAB (Mathworks, Natick, MA). Epileptiform activity ΔF/F time courses were filtered to account for baseline drift of the signal. Then, a threshold was set according to each trace signal-to-noise ratio and ΔF/F values above threshold were defined as seizure-like events (SLEs). Fraction of time spent in SLEs as a function of time was be plotted in 5 min bins.

Immnunohistochemistry {#s4-11}
---------------------

Juvenile mice (16 to 25 days old) were anesthetized with 100 mg Ketamine/10 mg Xylazine i.p. per kg. Anesthesia was confirmed prior to intracardiac perfusion with PBS 1X followed by 4% paraformaldehyde (PFA) in PBS pH 7.4. Brains were immediately extracted, fixed overnight in 4% PFA at 4°C and, cryoprotected in 30% sucrose in PBS for 48 hr at 4°C, embedded in Tissue-TeK OCT (Sakura) and frozen on dry ice. Coronal or horizontal tissue sections (30 µm thick) were cut with cryostat.

Primary and secondary antibodies were prepared in blocking solution (PBS with 0.1% Triton, 10% FBS and 3 mg/ml BSA). Brain sections were treated with blocking solution for 3 hr at room temperature, incubated with BAD primary antibody (1:100, Abcam ab32445) overnight at 4°C and with secondary anti-rabbit (1:1000, Sigma SAB4600107) for 1 hr at room temperature. Tissue sections were mounted with Vectashield Mounting Medium with DAPI (Vector Laboratories). Sections were imaged using an Olympus VS120 microscope and the secondary antibody's CF 594 fluorescence was excited with 594 nm light. For all representative images displayed in the figures, experiments were successfully repeated three or more times.

Data and statistical analysis {#s4-12}
-----------------------------

The number of independent experiments (n) is indicated in each figure. For calcium imaging data, number of animals (N) is also reported. For electrophysiology experiments, sample sizes were based on previous studies ([@bib41]); for calcium imaging experiments, sample sizes and power analysis were not determined in advance due to lack of knowledge of variability and likely effect sizes. In boxplots, central line indicates the median; bottom and top edges of the box indicate the 25th and 75th percentiles, respectively; whiskers extend to all data points not considered outliers; open symbols indicate outliers; and shaded area indicates 95% confidence intervals. Other summary data are presented as mean ± SEM, as indicated. Data were normally distributed and statistical significance was determined using two-tailed Student's t test or 1-way ANOVA with Bonferroni *post hoc* test as indicated. Statistical analyses were performed using MATLAB (Mathworks, Natick, MA) or Origin 9.1 (OriginLab, Northampton, MA, USA).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"BAD and K~ATP~ channels regulate neuron excitability and epileptiform activity\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

This work clearly builds on the investigators\' previous work on K-ATP channels and BAD regulation in the context of epilepsy.

Reviewer \#1:

The current study \"BAD and KATP channels regulate neuron excitability and epileptiform activity\", is a logical extension prior work by the group (Gimenez-Cassina et al., 2012). The study uses a combination of genetic and viral vector strategies to investigate cell autonomous regulation of BAD and its effect on neuronal excitability and seizures in an in vitro model. EC-Hippocampal slices were treated with picrotoxin to induce disinhibition and generate seizure-like activity in vitro. Regional variations in seizure-like activity were examined by imaging GCaMP signals in distinct sub-regions of hippocampus and entorhinal cortex (EC). The data demonstrate cell-specific regulation of KATP currents by BAD and identify that selective BAD knockdown localized to the dentate reduces in vitro seizure-like activity in the EC-Hippocampal loop. This careful study is an important extension of prior work.

Essential revisions:

1\) Disinhibition is used as the primary modality to induce seizure-like events. The experiments using glibenclamide and Kir6.2 knockouts confirm that KATP channels contribute to the reduction in seizure-like events in young BAD knockout mice. However, BAD knockouts have been shown to exhibit altered glutamatergic plasticity (Jiao and Li, 2011) and using disinhibition to generate seizures does not eliminate possibility that genotype-specific differences in glutamatergic circuits contribute to differences in seizure phenotype. Additionally, different concentrations of picrotoxin were needed to elicit seizure-like events young versus adult slices. Despite high levels of picrotoxin, seizures in adult mice appear considerably less robust suggesting that developmental changes in GABA reversal could complicate interpretation of the disinhibition model in young vs. adult mice. Thus, experiments using 4AP or 0Mg, which induce seizures without blocking inhibition, would help confirm that the primary finding reported in [Figure 3](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"} can be generalized to other in seizure models.

2\) The authors demonstrate that cell-specific knockdown of BAD in dentate granule cells reduces seizure-like activity in all regions of the EC-Hippo slice and propose that these data indicate that the dentate acts as a gate to the spread of seizures through the EC-Hippocampal loop. However, in the EC-Hippo slice prep, blocking seizure spread through any region within the trisynaptic loop should prevent re-entrant activity and reduce seizure duration, regardless of the specific circuit involved. Thus, in order to confirm a central role for the dentate as a seizure gate, it is necessary to demonstrate that deleting BAD in CA1 or CA3 does not similarly limit seizure activity. Again, a model where inhibition is not compromised would be appropriate for these studies as the inhibitory regulation is integral to the dentate gate.

Reviewer \#2:

Martínez-François et al., describe the effects of reducing BAD levels, in particular in DG granule cells on the generation of seizure-like events (SLE) in combined entorhinal cortex/hippocampal slices exposed to the GABA-A receptor antagonist picrotoxin. The authors show that reduced BAD levels lead to the activation of K(ATP) channels, which in turn reduce cellular excitability and confer resistance to seizures. Although the ideas behind the study are sound, the execution of it leaves a lot to be desired.

1\) The problem in general is the induction of SLE in slices. The authors use large-scale intracellular Ca^2+^ change measurements in various subfields of the slices as a proxy for recording electrical events. The ROIs are quite large and the neuronal populations showing the Ca^2+^ changes are quite heterogeneous. Considering that isolated CA3 and CA1 regions alone show SLE when exposed to picrotoxin, it is difficult to understand how the increase in K(ATP) activity secondary to regional deletion of BAD in dentate granule neurons can reduce the occurrence of SLE in the two hippocampal regions to the levels of the global BAD KOs. Moreover, it is inexplicable that the dentate gate effect manifests itself even to the upstream regions (MEC and LEC) when these regions are exposed to picrotoxin. A better approach would have been to expose only the EC to some convulsant drug without letting it propagate to the DG and CA3/1. An even better approach would have been to test the effects of knocking out BAD in the DG neurons in a chronic model of epilepsy. Only under the latter circumstances can meaningful conclusions be drawn about the role of BAD/K(ATP) in DG granule neurons on seizure generation and propagation.

2\) The immunohistochemical evidence for BAD deletion solely in the DG granule neurons is very poor. It is not clear what method for visualization was used for the secondary Ab, but the panels (B-D) in [Figure 5](#fig5){ref-type="fig"} are far from convincing for a specific KO of BAD.

3\) Since quite large changes in K currents are reported, it would help to see some raw data on the ramps that yielded the measurements.

4\) Glibenclamide is sometimes used at a concentration of 100 nM, other times at 200 nM. There is no mention in the methods if the DMSO concentration was adjusted in the vehicle controls.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"BAD and K~ATP~ channels regulate neuron excitability and epileptiform activity\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Richard Aldrich (Senior editor) and a Reviewing editor.

The manuscript has been evaluated by a new reviewing editor who identifies some remaining issues that need to be addressed before acceptance, as outlined below:

I think this is a very interesting manuscript. It does follow strongly on the previous study (Giménez-Cassina et al., 2012), but it shows new and more mechanistic attributes of many of the ideas inferred in that study and goes on to show that BAD deletion in the dentate is sufficient to reduce epileptiform activity, and that the mechanism is through increased K(ATP) currents.

I disagree with aspects of the previous reviews. The criticisms were with the mode of inducing epileptiform activity, but these concerns seem orthogonal to the main line of the investigation. As far as I can tell, the question being examined is, first, whether K(ATP) channels really are the pivot through which BAD manipulation exerts its effect. The previous published work showed an increase in K(ATP) single channels in BAD -/- cells, which was inferred to be a possible mechanism of seizure suppression in BAD KOs, but here we see the role of K(ATP) current investigated systematically, all the way to the effect of current blockade on firing in normal and BAD-lacking cells, which is crucial to understanding the mechanism regardless of the means by which seizure-like events are ultimately elicited. This is the first half of the manuscript, and the previous reviewers had no concerns with this. The second half of the manuscript tests whether K(ATP) modulation (including only in dentate gyrus) is the means by which BAD reduction is suppressive of seizure-like events. I know that people in the epilepsy field are highly focused on the epilepsy model used (and probably rightly so) but the previous work already showed that BAD KO was seizure suppressive both in kainate models and in disinhibitory models, so this manuscript is really beyond the realm of epilepsy models and is digging toward mechanism. So here, I think it is more than adequate to use a disinhibitory model and demonstrate that a BAD -/- mediated K(ATP) current increase (in the dentate gyrus alone) is a sufficient switch to suppress seizure-like events.

The only part that I agree with reviewer 2 on is that the authors could provide some further commentary on the fact that BAD suppression in the DG reduces seizure like events in upstream regions (MEC and LEC). I acknowledge their statement that \'the fact that the results are surprising does not invalidate them\' but the authors can help us think about what the results mean. Is it possible that there is some additional BAD knockdown in the EC? I think that is what reviewer 2 was driving at with the concern about [Figure 5](#fig5){ref-type="fig"}. Or might the result imply some recurrent activity or feedback in the slice? Perhaps the authors can expand on the brief statement in the Discussion section, which may contain an answer, but is somewhat cryptic at present. I can see how the reviewer\'s comment made them dig in their heels but that does not do a great service to the science in the long term. A more thorough discussion of this point for a sincerely interested reader would be sufficient.

10.7554/eLife.32721.018

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> The current study \"BAD and KATP channels regulate neuron excitability and epileptiform activity\", is a logical extension prior work by the group (Gimenez-Cassina et al., 2012). The study uses a combination of genetic and viral vector strategies to investigate cell autonomous regulation of BAD and its effect on neuronal excitability and seizures in an in vitro model. EC-Hippocampal slices were treated with picrotoxin to induce disinhibition and generate seizure-like activity in vitro. Regional variations in seizure-like activity were examined by imaging GCaMP signals in distinct sub-regions of hippocampus and entorhinal cortex (EC). The data demonstrate cell-specific regulation of KATP currents by BAD and identify that selective BAD knockdown localized to the dentate reduces in vitro seizure-like activity in the EC-Hippocampal loop. This careful study is an important extension of prior work.

We are glad that the reviewer agrees with our central conclusions and recognizes the importance of the current work.

> Specific comments:
>
> 1\) Disinhibition is used as the primary modality to induce seizure-like events. The experiments using glibenclamide and Kir6.2 knockouts confirm that KATP channels contribute to the reduction in seizure-like events in young BAD knockout mice. However, BAD knockouts have been shown to exhibit altered glutamatergic plasticity (Jiao and Li, 2011) and using disinhibition to generate seizures does not eliminate possibility that genotype-specific differences in glutamatergic circuits contribute to differences in seizure phenotype.

We now mention the earlier work describing reduced LTD in the BAD knockouts (subsection "BAD and K~ATP~ channels regulate entorhinal-hippocampal epileptiform activity"). We also point out that our results actually do rule out a contribution of such an effect to the seizure phenotype in slices, since blockade or deletion of KATP channels completely abolishes the difference in phenotype (and any alteration in glutamatergic circuits should remain). Additionally, because disinhibition leaves glutamatergic signaling intact, it should be the ideal approach to reveal such effects.

> Additionally, different concentrations of picrotoxin were needed to elicit seizure-like events young versus adult slices. Despite high levels of picrotoxin, seizures in adult mice appear considerably less robust suggesting that developmental changes in GABA reversal could complicate interpretation of the disinhibition model in young vs. adult mice. Thus, experiments using 4AP or 0Mg, which induce seizures without blocking inhibition, would help confirm that the primary finding reported in [Figure 3](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"} can be generalized to other in seizure models.

The seizure-like activity in adult mice is quite robust with the higher levels of picrotoxin, as is the effect of BAD knockout. We now show examples of the primary data in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. We have discussed the likely reasons that the higher picrotoxin concentration is necessary (as the reviewer suggests, developmental changes in GABAergic signaling are likely the reason). We do not agree, however, that the interpretation is complicated by the use of disinhibition: in fact, our results show that the effects of BAD knockout are robust in the adult animals as well as the juveniles.

We considered the use of 4AP or 0Mg models, as described in the text, but found them to be less consistent at producing seizure-like behavior (and they also frequently produce spreading depression). While repeating all of our experiments with one of these models would indeed confirm that the results "can be generalized", we would argue that these very extensive new experiments are unnecessary for the conclusions of the paper.

> 2\) The authors demonstrate that cell-specific knockdown of BAD in dentate granule cells reduces seizure-like activity in all regions of the EC-Hippo slice and propose that these data indicate that the dentate acts as a gate to the spread of seizures through the EC-Hippocampal loop. However, in the EC-Hippo slice prep, blocking seizure spread through any region within the trisynaptic loop should prevent re-entrant activity and reduce seizure duration, regardless of the specific circuit involved. Thus, in order to confirm a central role for the dentate as a seizure gate, it is necessary to demonstrate that deleting BAD in CA1 or CA3 does not similarly limit seizure activity. Again, a model where inhibition is not compromised would be appropriate for these studies as the inhibitory regulation is integral to the dentate gate.

We have been carefully conservative in our conclusions about the dentate gate. We show (as the reviewer agrees) that targeted knockout of BAD in DGNs can produce the full antiseizure effect of BAD in the slice. We have said that these data are consistent with previous literature about the possible role of the dentate in gating seizure activity, because BAD knockout in DGNs is *sufficient* to produce an anti-seizure effect. We certainly do not claim an *exclusive* role of the dentate in seizure gating (which would require the extensive new experiments that the reviewer mentions).

Interestingly, this reviewer argues that blocking seizure spread anywhere in the region should block seizure-like events, while the other reviewer points out that other isolated regions of hippocampus exposed to picrotoxin can sustain seizure-like events (and therefore that it should be impossible for a dentate-specific manipulation to have the effect we observe). Clearly there is disagreement about what is "expected" in this model. But we would argue that this makes the very clear outcome of our experiments even more remarkable.

Additionally, we do not agree that a "model where inhibition is not compromised" would provide better evidence that the dentate can act as a gate. According to the reviewer, inhibitory regulation is central to the dentate gate, and thus we have probably produced seizure-like events by compromising the function of the dentate gate. It therefore appears from our results that we have successfully restored the gate function of the dentate by knocking out BAD and increasing KATP channel activity in dentate granule neurons.

> Reviewer \#2:
>
> Martínez-François et al., describe the effects of reducing BAD levels, in particular in DG granule cells on the generation of seizure-like events (SLE) in combined entorhinal cortex/hippocampal slices exposed to the GABA-A receptor antagonist picrotoxin. The authors show that reduced BAD levels lead to the activation of K(ATP) channels, which in turn reduce cellular excitability and confer resistance to seizures. Although the ideas behind the study are sound, the execution of it leaves a lot to be desired.

We are glad that the reviewer agrees with our central results.

> 1\) The problem in general is the induction of SLE in slices. The authors use large-scale intracellular Ca^2+^ change measurements in various subfields of the slices as a proxy for recording electrical events. The ROIs are quite large and the neuronal populations showing the Ca^2+^ changes are quite heterogeneous.

Most previous work on SLEs in slices uses several individual extracellular electrodes to record the events. We think it is clear that the widefield Ca measurements provide similar (actually more extensive) information about patterns of activity, and we demonstrate that the Ca events coincide with extracellular recordings ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In any case, the reviewer does not make it clear why this could be a problem for our conclusions.

> Considering that isolated CA3 and CA1 regions alone show SLE when exposed to picrotoxin, it is difficult to understand how the increase in K(ATP) activity secondary to regional deletion of BAD in dentate granule neurons can reduce the occurrence of SLE in the two hippocampal regions to the levels of the global BAD KOs. Moreover, it is inexplicable that the dentate gate effect manifests itself even to the upstream regions (MEC and LEC) when these regions are exposed to picrotoxin.

In contrast with the earlier reviewer, this reviewer finds it very surprising that increased KATP channel activity in DGNs alone can produce the effect we observe on whole slice seizure-like activity. But the fact that our results are surprising ("difficult to understand" or "inexplicable") does not invalidate them in any way. (And the other reviewer certainly did not find the outcomes to be inexplicable.) We believe that the results are quite clear, and the reviewer has not said otherwise.

> A better approach would have been to expose only the EC to some convulsant drug without letting it propagate to the DG and CA3/1.

It is not clear why this (unusual) approach would be better, except perhaps to give a result that would be more in line with the reviewer's expectations.

> An even better approach would have been to test the effects of knocking out BAD in the DG neurons in a chronic model of epilepsy. Only under the latter circumstances can meaningful conclusions be drawn about the role of BAD/K(ATP) in DG granule neurons on seizure generation and propagation.

We have recently shown that BAD knockout indeed has antiseizure effects in (whole) mice with the *Kcna1*^−/−^ genetic model of epilepsy. But it would not be practical to perform the slice level experiments with this model, because the frequency of events would likely be very variable between animals and much lower than with the picrotoxin approach used here. Moreover, we disagree that this major new experimental campaign is necessary to make meaningful conclusions.

> 2\) The immunohistochemical evidence for BAD deletion solely in the DG granule neurons is very poor. It is not clear what method for visualization was used for the secondary Ab, but the panels (B-D) in [Figure 5](#fig5){ref-type="fig"} are far from convincing for a specific KO of BAD.

We disagree that the evidence is poor, and are not sure why the reviewer thinks that our method is unclear, as it is completely described in the paper.

Immunofluorescence of the hippocampus needs to be examined carefully, because the high density of nuclei in the DG and pyramidal cell layers causes them always to appear partially unstained. But careful examination of the images makes it very clear that the cytosolic signal present in the controls is absent in the targeted knockout, in the dentate granule neurons but not in other parts of the hippocampus. We have provided additional images in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. We also point out that the BAD signal is noticeably diminished in the molecular layer of the dentate gyrus (which contains the DGN dendrites), but not elsewhere in the slice or in the parental controls.

> 3\) Since quite large changes in K currents are reported, it would help to see some raw data on the ramps that yielded the measurements.

These data are now shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.

> 4\) Glibenclamide is sometimes used at a concentration of 100 nM, other times at 200 nM. There is no mention in the methods if the DMSO concentration was adjusted in the vehicle controls.

This was a typographical error in one of the figure legends, and it has been corrected.

\[Editors\' note: the author responses to the re-review follow.\]

> \[...\] The only part that I agree with reviewer 2 on is that the authors could provide some further commentary on the fact that BAD suppression in the DG reduces seizure like events in upstream regions (MEC and LEC). I acknowledge their statement that \'the fact that the results are surprising does not invalidate them\' but the authors can help us think about what the results mean. Is it possible that there is some additional BAD knockdown in the EC? I think that is what reviewer 2 was driving at with the concern about [Figure 5](#fig5){ref-type="fig"}. Or might the result imply some recurrent activity or feedback in the slice? Perhaps the authors can expand on the brief statement in the Discussion section, which may contain an answer, but is somewhat cryptic at present.

We have added [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} and the following paragraphs to the Discussion section to expand on these issues:

"Our immunostaining results show robust BAD knockout in DGNs (including stratum lucidum, which contains the mossy fiber projections from DGNs) of Bad^flox/flox^; Dock10-Cre mice compared to the parental controls ([Figure 5](#fig5){ref-type="fig"}). This targeted Bad knockout had no discernable effect on BAD expression elsewhere in the brain slices we examined. We cannot rule out that very sparse expression of Dock10-Cre in the EC (Allen Institute Mouse Brain Atlas; expression of Dock10) could affect some cells, however, the absence of Bad throughout the DGN layer of Bad^flox/flox^; Dock10-Cre mice, together with the substantial effect on the seizure-like activity, seems most consistent with a primary effect of the dentate acting as a seizure gate, as suggested previously from both in vitro and in vivo experiments (Dengler and Coulter, 2016; Heinemann et al., 1992; Hsu, 2007; Krook-Magnuson et al., 2015, 2013; Lothman et al., 1992). Interestingly, seizure-like activity is decreased in all areas (including EC) of the EC-HC slices upon BAD knockout specifically in DGNs; as previously mentioned this could reflect the recurrent nature of the EC-HC circuit where the dentate gate could decrease reentrant excitation into the EC. Taken together, these observations illuminate a mechanism by which neuronal metabolism can regulate neuronal excitability to produce seizure protection."

"We also observed that in adults, BAD-mediated seizure resistance is more limited to the hippocampal region and is not as prominent in the EC ([Figure 4](#fig4){ref-type="fig"}). This pattern is consistent with BAD-mediated reinforcement of a dentate gate that limits invasion of elevated EC activity into the hippocampus. The fact that in juvenile slices, DGN-specific deletion of BAD also affected EC activity may indicate that, at the lower levels of disinhibition (lower \[picrotoxin\]), recurrent excitation from the hippocampus to EC is more relevant than in adult slices."
